A lease by a venture capital-backed New Haven biotech company gives the Winchester Works lab conversion 93,000 square feet of total life science space commitments to date.
Artizan Biosciences will relocate from 25 Science Park to 10,000 square feet at Winchester Works as it continues research on a product candidate to treat inflammatory bowel disease. The company was founded by researchers from Yale University and received $11 million in series A-2 financing led by Hatteras Venture Partners and Biohaven Therapeutics Ltd. in 2021.
The lab-ready updates to the former office complex, originally a firearms factory, received its first tenant commitment in November when Halda Therapeutics leased 9,800 square feet.
In January, Guilford-based Quintum-Si Inc. leased 65,000 square feet at Winchester Works for a relocated and expanded headquarters.
The lab conversion is a joint venture of Twining Properties, L+M Development Partners affiliate LMXD and Goldman Sachs Urban Investment Group.
“As we continue to grow our staff and expand our clinical efforts, moving to Winchester Works allows us to accelerate our research efforts. We’re excited to remain in the burgeoning life sciences community of New Haven and close to the company’s beginnings at Yale University,” Artizan CEO Bridget Martell said in a statement.